Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.40 |
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | GRK5 | P34947 | 3/20 | 0.37 |
| ▸ | GRK2 | P25098 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100605 | 0.93 | MET (0.43) | FGFR1FGFR2FGFR3METJAK2 | |
| SCHEMBL10100602 | 0.88 | LRRK2 (0.41) | FGFR1FGFR2FGFR3MET | |
| SCHEMBL10100603 | 0.85 | LRRK2 (0.45) | FGFR1FGFR2FGFR3MET | |
| SCHEMBL10100785 | 0.84 | LRRK2 (0.40) | FGFR1FGFR2FGFR3MET | |
| SCHEMBL10100619 | 0.84 | MAPK1 (0.39) | FGFR1FGFR2FGFR3METJAK2 | |
| SCHEMBL12538817 | 0.82 | FGFR1 (0.59) | FGFR1FGFR2FGFR3MAP4K3ALK | |
| SCHEMBL13423976 | 0.81 | MAP4K3 (0.40) | FGFR1FGFR2FGFR3MAP4K3ALK | |
| SCHEMBL10100783 | 0.81 | LRRK2 (0.43) | FGFR1FGFR2FGFR3MET | |
| SCHEMBL10100604 | 0.79 | EPHX2 (0.44) | — | |
| SCHEMBL10100465 | 0.78 | JAK2 (0.45) | FGFR1FGFR2FGFR3METJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | FGFR1 133/4885FGFR2 177/4885FGFR3 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.